Therapeutic potential of triheptanoin in metabolic and neurodegenerative diseases

In the past 15 years the potential of triheptanoin for the treatment of several human diseases in the area of clinical nutrition has grown considerably. Use of this triglyceride of the odd‐chain fatty acid heptanoate has been proposed and applied for the treatment of several conditions in which the energy supply from citric acid cycle intermediates or fatty acid degradation are impaired. Neurological diseases due to disturbed glucose metabolism or metabolic diseases associated with impaired β‐oxidation of long chain fatty acid may especially take advantage of alternative substrate sources offered by the secondary metabolites of triheptanoin. Epilepsy due to deficiency of the GLUT1 transporter, as well as diseases associated with dysregulation of neuronal signalling, have been treated with triheptanoin supplementation, and very recently the advantages of this oil in long‐chain fatty acid oxidation disorders have been reported. The present review summarises the published literature on the metabolism of triheptanoin including clinical reports related to the use of triheptanoin.

[1]  M. Hodson,et al.  Triheptanoin alters [U-13C6]-glucose incorporation into glycolytic intermediates and increases TCA cycling by normalizing the activities of pyruvate dehydrogenase and oxoglutarate dehydrogenase in a chronic epilepsy mouse model , 2020, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  P. Laforêt,et al.  No effect of triheptanoin on exercise performance in McArdle disease , 2019, Annals of clinical and translational neurology.

[3]  L. Rocha,et al.  Drug-resistant epilepsy: From multiple hypotheses to an integral explanation using preclinical resources , 2019, Epilepsy & Behavior.

[4]  K. J. Fogle,et al.  Ketogenic and anaplerotic dietary modifications ameliorate seizure activity in Drosophila models of mitochondrial encephalomyopathy and glycolytic enzymopathy. , 2019, Molecular genetics and metabolism.

[5]  P. Kwan,et al.  Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy , 2019, Epilepsia open.

[6]  R. Schiffmann,et al.  A double-blind, placebo-controlled trial of triheptanoin in adult polyglucosan body disease and open-label, long-term outcome , 2018, Journal of Inherited Metabolic Disease.

[7]  K. Borges,et al.  Impairments in Oxidative Glucose Metabolism in Epilepsy and Metabolic Treatments Thereof , 2018, Front. Cell. Neurosci..

[8]  K. Borges,et al.  A pilot study of add-on oral triheptanoin treatment for children with medically refractory epilepsy. , 2018, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[9]  K. Borges,et al.  Heptanoate is neuroprotective in vitro but triheptanoin post-treatment did not protect against middle cerebral artery occlusion in rats , 2018, Neuroscience Letters.

[10]  I. Scheffer,et al.  Epilepsy , 2018, Nature Reviews Disease Primers.

[11]  K. Borges,et al.  Triheptanoin protects against status epilepticus‐induced hippocampal mitochondrial dysfunctions, oxidative stress and neuronal degeneration , 2018, Journal of neurochemistry.

[12]  J. Kirschner,et al.  Mitochondrial fatty acid biosynthesis and muscle fiber plasticity in very long‐chain acyl‐CoA dehydrogenase‐deficient mice , 2018, FEBS letters.

[13]  M. Vidailhet,et al.  A randomized, controlled, double-blind, crossover trial of triheptanoin in alternating hemiplegia of childhood , 2017, Orphanet Journal of Rare Diseases.

[14]  M. Iruela-Arispe,et al.  Membrane lipids and cell signaling , 2017, Current opinion in lipidology.

[15]  J. Vissing,et al.  Treatment Opportunities in Patients With Metabolic Myopathies , 2017, Current Treatment Options in Neurology.

[16]  J. DeLany,et al.  Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial , 2017, Journal of Inherited Metabolic Disease.

[17]  F. Mochel.  Triheptanoin for the treatment of brain energy deficit: A 14‐year experience , 2017, Journal of neuroscience research.

[18]  H. Lerche,et al.  The role of genetic testing in epilepsy diagnosis and management , 2017, Expert review of molecular diagnostics.

[19]  P. Escribá,et al.  Triacylglycerol mimetics regulate membrane interactions of glycogen branching enzyme: implications for therapy[S] , 2017, Journal of Lipid Research.

[20]  K. Borges,et al.  Alternative Fuels in Epilepsy and Amyotrophic Lateral Sclerosis , 2017, Neurochemical Research.

[21]  J. Vockley,et al.  UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatment. , 2017, Molecular genetics and metabolism.

[22]  S. Tucci.  Very long-chain acyl-CoA dehydrogenase (VLCAD-) deficiency–studies on treatment effects and long-term outcomes in mouse models , 2017, Journal of Inherited Metabolic Disease.

[23]  C. Dejong,et al.  The odd-carbon medium-chain fatty triglyceride triheptanoin does not reduce hepatic steatosis. , 2017, Clinical nutrition.

[24]  S. Tucci,et al.  Triheptanoin: long-term effects in the very long-chain acyl-CoA dehydrogenase-deficient mouse[S] , 2016, Journal of Lipid Research.

[25]  J. Charrow,et al.  Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders. , 2016, Molecular genetics and metabolism.

[26]  K. Borges,et al.  Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis , 2016, PloS one.

[27]  K. Borges,et al.  Modification of Astrocyte Metabolism as an Approach to the Treatment of Epilepsy: Triheptanoin and Acetyl-l-Carnitine , 2016, Neurochemical Research.

[28]  C. Roe,et al.  Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: Review of 15 years Experience. , 2015, Molecular genetics and metabolism.

[29]  R. Schiffmann,et al.  Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[30]  S. Tucci,et al.  De novo fatty acid biosynthesis and elongation in very long‐chain acyl‐CoA dehydrogenase‐deficient mice supplemented with odd or even medium‐chain fatty acids , 2015, The FEBS journal.

[31]  J. Klein,et al.  Reduced severity of ischemic stroke and improvement of mitochondrial function after dietary treatment with the anaplerotic substance triheptanoin , 2015, Neuroscience.

[32]  Romain Valabregue,et al.  Triheptanoin improves brain energy metabolism in patients with Huntington disease , 2015, Neurology.

[33]  A. Sherry,et al.  The ratio of acetate‐to‐glucose oxidation in astrocytes from a single 13C NMR spectrum of cerebral cortex , 2015, Journal of neurochemistry.

[34]  Min Jung Park,et al.  Anaplerotic Triheptanoin Diet Enhances Mitochondrial Substrate Use to Remodel the Metabolome and Improve Lifespan, Motor Function, and Sociability in MeCP2-Null Mice , 2014, PloS one.

[35]  Jason Y. Park,et al.  Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement. , 2014, JAMA neurology.

[36]  P. Leone,et al.  Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease , 2014, Journal of Inherited Metabolic Disease.

[37]  J. Walter,et al.  Unsuccessful treatment of severe pyruvate carboxylase deficiency with triheptanoin , 2014, European Journal of Pediatrics.

[38]  M. Vidailhet,et al.  GLUT1 deficiency syndrome: an update. , 2014, Revue neurologique.

[39]  M. Hodson,et al.  Alterations of Hippocampal Glucose Metabolism by Even versus Uneven Medium Chain Triglycerides , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  P. Rijken,et al.  Checks and balances in membrane phospholipid class and acyl chain homeostasis, the yeast perspective. , 2013, Progress in lipid research.

[41]  I. Ferrer,et al.  Triheptanoin supplementation to ketogenic diet curbs cognitive impairment in APP/PS1 mice used as a model of familial Alzheimer's disease. , 2013, Current Alzheimer research.

[42]  L. Good,et al.  Heptanoate as a Neural Fuel: Energetic and Neurotransmitter Precursors in Normal and Glucose Transporter I-Deficient (G1D) Brain , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[43]  C. Reid,et al.  Triheptanoin reduces seizure susceptibility in a syndrome-specific mouse model of generalized epilepsy , 2013, Epilepsy Research.

[44]  L. Good,et al.  Glut1 deficiency (G1D): Epilepsy and metabolic dysfunction in a mouse model of the most common human phenotype , 2012, Neurobiology of Disease.

[45]  K. Borges,et al.  Triheptanoin—A medium chain triglyceride with odd chain fatty acids: A new anaplerotic anticonvulsant treatment? , 2012, Epilepsy Research.

[46]  J. Klepper.  GLUT1 deficiency syndrome in clinical practice , 2012, Epilepsy Research.

[47]  K. Borges,et al.  Triheptanoin in acute mouse seizure models , 2012, Epilepsy Research.

[48]  K. Borges,et al.  Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models , 2010, Neurobiology of Disease.

[49]  W. Blume.  Focal and Generalized: Both Here and There , 2010, Epilepsy currents.

[50]  A. Durr,et al.  Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington's disease , 2010, European Journal of Human Genetics.

[51]  Guo-Fang Zhang,et al.  Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats . II . Effects on lipolysis , glucose production , and liver acyl-CoA profile , 2010 .

[52]  T. Bottiglieri,et al.  Adult Polyglucosan Body Disease (APBD): Anaplerotic diet therapy (Triheptanoin) and demonstration of defective methylation pathways. , 2009, Molecular genetics and metabolism.

[53]  A. Sant'ana,et al.  [Hepatoprotective effect of diheptanoin and tritreptanoin chronic consumption against steatosis in rats]. , 2008, Arquivos brasileiros de endocrinologia e metabologia.

[54]  C. Roe,et al.  Carnitine palmitoyltransferase II deficiency , 2008, Neurology.

[55]  D. Thurman,et al.  How common are the “common” neurologic disorders? , 2007, Neurology.

[56]  G. Kutz,et al.  Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. , 2006, American journal of physiology. Endocrinology and metabolism.

[57]  F. Mochel,et al.  Anaplerotic diet therapy in inherited metabolic disease: Therapeutic potential , 2006, Journal of Inherited Metabolic Disease.

[58]  C. Roe,et al.  Anaplerotic molecules: Current and future , 2006, Journal of Inherited Metabolic Disease.

[59]  F. Mochel,et al.  Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy. , 2005, Molecular genetics and metabolism.

[60]  C. Roe,et al.  Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. , 2002, The Journal of clinical investigation.

[61]  K. Alberti,et al.  Pyruvate carboxylase deficiency , 1984, Journal of Inherited Metabolic Disease.

[62]  L. Deenen,et al.  Membrane asymmetry and blood coagulation , 1977, Nature.

[63]  G. Enns,et al.  Triheptanoin: A Rescue Therapy for Cardiogenic Shock in Carnitine-acylcarnitine Translocase Deficiency. , 2018, JIMD reports.

[64]  P. Legrand,et al.  Revisiting the metabolism and physiological functions of caprylic acid (C8:0) with special focus on ghrelin octanoylation. , 2016, Biochimie.